Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
| Image |  |
|---|---|
| Description | scientific article published in May 2017 |
| Author/s |
author: Jennifer Rubin Grandis Chaoyang Sun Neil H Bhola Shannon N. Westin Kwok-Shing Ng Zhenlin Ju Gordon B. Mills Joan Brugge |
| Publication date | May 1, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |